Professor, Internal Medicine, Mayo Medical School
Hematology
Dr. Svetomir N. Markovic, MD
|
|
Give Review
Doctor Svetomir N. Markovic, MD is an expert in the field of Hematology. Svetomir N. Markovic, MD is a published MD. He published 90 publications, including: 'The use of pembrolizumab for the treatment of metastatic uveal melanoma.' He is registered with Medicare.
Publications
- Large B-cell transformation in nodular lymphocyte predominant Hodgkin Lymphoma: forty-year experience from a single institution.
- The use of pembrolizumab for the treatment of metastatic uveal Melanoma.
- Gene expression patterns in CD4+ peripheral blood Cells in healthy subjects and stage IV melanoma patients.
- Definitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral Immunotherapy.
- Nab-paclitaxel in patients with metastatic Melanoma.
- Fetal sex-based differences in maternal hormones, angiogenic factors, and Immune mediators during pregnancy and the postpartum period.
- Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin Lymphoma.
- The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic uveal Melanoma.
- Oral capecitabine to prevent recurrent cutaneous squamous cell carcinoma in a Lung transplant recipient.
- c-MET expression in primary and Liver metastases in uveal melanoma.
- Infused Autograft Lymphocyte to Monocyte Ratio and Survival in Diffuse Large B-Cell Lymphoma.
- Untreated Stage IV Melanoma Patients Exhibit Abnormal Monocyte Phenotypes and Decreased Functional Capacity.
- Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outc...
- Inhibition of angiogenesis for the treatment of metastatic Melanoma.
- Dermal and conjunctival melanocytic proliferations in diffuse uveal melanocytic proliferation.
- Dominant Effects of Δ40p53 on p53 Function and Melanoma Cell Fate.
- Pediatric Melanoma: Analysis of an international registry.
- Increased Bowel Toxicity in Patients Treated With a Vascular Endothelial Growth Factor Inhibitor (VEGFI) After Stereotactic Body Radiation Therapy (SBRT).
- Up-regulation of pro-angiogenic factors and establishment of tolerance in malignant Pleural effusions.
- Absolute monocyte count at diagnosis and survival in mantle cell Lymphoma.
- Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.
- Endogenous tumor-reactive CD8(+) T Cells are differentiated effector Cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth.
- Rare Presentations of Primary Melanoma and Special Populations: A Systematic Review.
- Vulvar and vaginal melanoma: Case series and review of current management options including neoadjuvant chemotherapy.
- Percutaneous cryoablation of musculoskeletal oligometastatic Disease for complete remission.
- Treatment with low doses of polyclonal immunoglobulin improves B cell function during Immune reconstitution in a murine model.
- A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV Melanoma : A North Ce...
- Phase II Study of Temozolomide (TMZ) and Everolimus (RAD001) Therapy for Metastatic Melanoma: A North Central Cancer Treatment Group Study, N0675.
- Normal ageing is associated with an increase in Th2 Cells, MCP-1 (CCL1) and RANTES (CCL5), with differences in sCD40L and PDGF-AA between sexes.
- Is Age ≥ 70 Years an Important Predictor of Adverse Events Among Patients Enrolled in Metastatic Melanoma Trials? Findings from Pooled Analyses of Therapeutic Trials.
- Phase II Trial of Intravenous Administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma.
- An organ System based approach to prognosis in advanced melanoma.
- Fluctuation of Systemic immunity in melanoma and implications for timing of therapy.
- Vemurafenib for melanoma metastases to the Brain.
- BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced...
- The Absolute Monocyte Count is Associated with Overall Survival in Patients Newly Diagnosed with Follicular Lymphoma.
- Regional lymphatic immunity in Melanoma.
- Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory Lymphomas.
- Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as Immune adjuvants for a melanoma peptide vaccine.
- Mayo clinic consensus recommendations for the depth of excision in primary cutaneous Melanoma.
- Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell Lymphoma.
- A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1).
- Regional immunity in Melanoma: immunosuppressive changes precede nodal metastasis.
- Differential response of human and mouse dendritic Cells to VEGF determines interspecies discrepancies in tumor-mediated TH1/TH2 polarity shift.
- Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole Brain radiation therapy?
- A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a north central Cancer treatment group study, N057E1.
- Predicting survival for diffuse large B-cell Lymphoma patients using baseline neutrophil/lymphocyte ratio.
- Amplifying TLR-MyD88 signals within tumor-specific T Cells enhances antitumor activity to suboptimal levels of weakly immunogenic tumor antigens.
- Diagnosis and management of Waldenström Macroglobulinemia: Mayo stratification of Macroglobulinemia and risk-adapted therapy (mSMART) guidelines.
- A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant Melanoma: a phase 2 consortium study.
- Treatment with polyclonal immunoglobulin during T-Cell reconstitution promotes naive T-Cell proliferation.
- The use of pulsed dye laser in the treatment of Melanoma metastatic to the skin: a Mayo Clinic case series.
- Metastatic malignant Melanoma manifesting as an intracardiac mass.
- New-onset lymphopenia assessed during routine follow-up is a risk factor for relapse postautologous peripheral blood hematopoietic stem Cell transplantation in patient...
- Combination cytokine therapy inhibits tumor growth by generation of tumor-specific T-Cell responses in a murine melanoma model.
- Host immunity affects survival in myelodysplastic Syndromes: Independent prognostic value of the absolute lymphocyte count.
- Use of various offset settings in the Fenwal Amicus during hematopoietic progenitor Cell collection to increase lymphocyte yield and reduce cross-Cellular contamination.
- Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for Cancer therapeutic agents.
- B7-H1 (PD-L1, CD274) suppresses Host immunity in T-cell lymphoproliferative disorders.
- The pathway ahead in Melanoma trials.
- Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell Lymphoma.
- Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study...
- A dose-escalation study of aerosolized sargramostim in the treatment of metastatic Melanoma: an NCCTG Study.
- mTOR inhibitor monotherapy is insufficient to suppress viremia and Disease progression in Epstein-Barr virus-driven lymphoproliferative disorders (EBV-LPD).
- Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin Lymphoma: a prospective study.
- Meta-analysis of phase II cooperative group trials in metastatic stage IV Melanoma to determine progression-free and overall survival benchmarks for future phase II tr...
- A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic Melanoma.
- A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic Melanoma.
- Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
- AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin Lymphoma.
- Androgenic therapy for Waldenstrom's Macroglobulinemia.
- Peptide vaccination of patients with metastatic Melanoma: improved clinical outcome in patients demonstrating effective immunization.
- Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic Melanoma.
- A phase II study of bortezomib in the treatment of metastatic malignant Melanoma.
- Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary Systemic amyloidosis.
- Malignant basomelanocytic tumor manifesting as metastatic Melanoma.
- Clopidogrel-associated autoImmune thrombocytopenic purpura.
- Management of multifocal primary cutaneous CD30 anaplastic large cell Lymphoma.
- Therapeutic options in patients with Lymphoma and severe liver dysfunction.
- Aerosolized granulocyte macrophage colony-stimulating factor (GM-CSF) therapy in metastatic Cancer.
- Changing surgical therapy for Melanoma of the external ear.
- Chylothorax in chronic lymphocytic Leukemia patient.
- Phase II trial of KW2189 in patients with advanced malignant Melanoma.
- Challenges in the development of effective peptide vaccines for Cancer.
- Extracorporeal photopheresis and adjuvant aerosolized granulocyte-macrophage colony-stimulating factor for Sézary Syndrome.
- Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin Lymphoma.
- Infused autograft lymphocyte to monocyte ratio predicts survival in classical Hodgkin Lymphoma.
- Day 100 Peripheral Blood Absolute Lymphocyte/Monocyte Ratio and Survival in Classical Hodgkin's Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transp...
- Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin Lymphoma.
Schools
Medical College of Pennsylvania
Mayo Clinic Rochester
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Choice Plus POS II
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Blue Cross Accord
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Choice Care PPO
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Options PPO
Education
-
Mayo School of Graduate Medical Education
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1013981257 | |
| NPPES Provider LastName | MARKOVIC | |
| NPPES Provider FirstName | SVETOMIR | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Hematology | |
| Total Claim Count | 157.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1013981257 |
| Last Name Of The Provider | MARKOVIC |
| First Name Of The Provider | SVETOMIR |
| View All |
Similar Doctors
|
|
Dr. Philip R. Greipp, MD |
|
|
Dr. Lisa M. Baumann Kreuziger, MD |
|
|
Dr. Matthew S. Block, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karen L. Grogg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patricia T. Greipp, MD |
|
|
Dr. Scott H. Kaufmann, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Robert L. Phyliky, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wilson I. Gonsalves, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven I. Robinson, MD |
|
|
Dr. Jessemy D. Neiger, MD |
|
|
Dr. Cynthia J. Wetmore, MD |
|
|
Dr. Cassie L. Booth, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bruce E. Pollock, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Nanna H. Sulai, MD |
|
|
Morris A. Gertz |